Effect of antihypertensive agents on metabolic syndrome: a systematic review and meta-analysis / Efeitos de antihipertensivos na síndrome metabólica: uma revisão sistemática e metanálise

• Autor(a) principal: Lacerda, Luiz Muller
• Data de Publicação: 2021
• Outros Autores: Guerrieri, Yzamara Dutra, Lopes, Diego José, Lucca, Ana Beatriz Araújo, Carvalho, Marina Fernandes, e Silva, Vítor Rodrigues Ribeiro, de Macedo, Leandro Roberto, de Matos, Ione Maria
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Health Review
• Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/40326
• topic: Metabolic Syndrome; Antihypertensive Agents; Systematic Review; Meta-Analysis.

Background: Metabolic syndrome (MetS) is a chronic disease defined by a set of genetic and environmental factors that determine high cardiovascular risk, being highly prevalent in hypertensive patients. Aim: To identify the efficacy of the association of antihypertensive drugs in hypertensive individuals with MetS. Methods: The systematic review searching the electronic databases Medline/PubMed, Lilacs, BVS and Periódicos Capes with articles published from 2010 to 2020. The registration number of this review at PROSPERO is CRD42021235614. Original articles and clinical randomized trials were included in present review. To calculate the meta-analytic effect measure was used the absolute difference between means using the random effects model with 95% confidence interval. Results: Eight articles were included in this review totaling data from 2,625 patients. In six papers was performed meta-analysis. The selected studies suggest that most combinations of antihypertensive drug classes reduced blood pressure to satisfactory values, and some combinations reduced markers of inflammation, improved lipid and glycemic parameters and reduced the risk of developing diabetes mellitus. The combination therapies between angiotensin receptor blockers (ARB) and calcium channel blockers (CCB), as well as, the combination between CCB and angiotensin converting enzyme inhibitors (ACEI) were well-tolerated and showed satisfactory results in hypertensive patients with metabolic syndrome. Conclusion: based on the results of the present study, we would like to suggest that further studies be carried out to assess the efficacy of the combination between irbesartan and manidipine (ARB and CCB), manidipine and Lisinopril (CCB and ACEI), and between enalapril and lercadipine (ACEI and CCB). These drugs have shown satisfactory results for use in hypertensive patients with MetS.